168 related articles for article (PubMed ID: 26168497)
1. Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.
Maehara M; Ueda T; Miyahara D; Takahashi Y; Miyata K; Nam SO; Katsuda T; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4527-34. PubMed ID: 26168497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
5. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
10. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
Osorio-Sanchez JA; Karapetis C; Koczwara B
Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
13. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
Nasu R; Nannya Y; Kurokawa M
Int J Hematol; 2015 Apr; 101(4):376-85. PubMed ID: 25644148
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
17. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
[TBL] [Abstract][Full Text] [Related]
18. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
19. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
20. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
